Salvage Chemotherapy in Recurrent Cervical Cancer With Biweekly Pegylated Liposomal Doxorubicin (Lipo-Dox)

Objective: To investigate the objective response rate to and tolerance of biweekly Lipo-Dox (TTY Biopharm Co. Ltd., Taipei, Taiwan) at a dosage of 20 mg/m2 in previously treated patients with recurrent cervical cancer. Materials and Methods: This study was performed as a Simon's two-stage phase...

Full description

Bibliographic Details

Published in:	Taiwanese Journal of Obstetrics & Gynecology
Main Authors:	Jen-Ruei Chen, Yuh-Cheng Yang, Tze-Chien Chen, Jerry Cheng-Yen Lai, Shing-Jyh Chang, Chi-Long Chang, Kung-Liahng Wang
Format:	Article
Language:	English
Published:	Elsevier 2008-09-01
Subjects:	cervical cancer chemotherapy Lipo-Dox recurrent liposomal doxorubicin
Online Access:	http://www.sciencedirect.com/science/article/pii/S1028455908601321